Skip to main content
Aclaris starts 100-patient modzatinib lichen planus trial
Image for illustrative purposes only. Not a real photo.

Aclaris starts 100-patient modzatinib lichen planus trial

By

Key points

  • Aclaris Therapeutics (NASDAQ:ACRS) initiated its Phase 2b ALPHA trial of modzatinib in moderate-to-severe lichen planus, beginning with patients with oral erosive disease.
  • The randomized study will assess two dose levels against placebo in approximately 100 participants across three disease groups.
  • Aclaris expects oral-cohort results in the second half of 2027, while ATI-9494 and ATI-052 have additional clinical development milestones planned for 2027.

Aclaris Therapeutics (NASDAQ:ACRS) has initiated its Phase 2b ALPHA trial of modzatinib in moderate-to-severe lichen planus, beginning with the oral erosive disease cohort.

The randomized, double-blind, placebo-controlled study will evaluate two dose levels in approximately 100 participants with biopsy-confirmed disease that remains inadequately controlled by topical treatments.

The trial covers three lichen planus groups: oral erosive disease, cutaneous disease and lichen planopilaris, with primary disease-activity assessments scheduled for Week 16 in the first two cohorts and Week 24 in the scalp disease cohort.

Modzatinib already has U.S. Food and Drug Administration Fast Track Designation for moderate-to-severe lichen planus, including oral erosive disease, cutaneous disease and lichen planopilaris.

Aclaris expects top-line results from the oral erosive cohort in the second half of 2027, while it expects to submit an investigational new drug application for ATI-9494 in the fourth quarter of 2026.

The company also plans to initiate an ATI-9494 clinical trial and a Phase 2b ATI-052 trial in eosinophilic esophagitis in the first quarter of 2027.


Frequently asked questions